Compare CDW Corp. (CDW) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CDW Corp. vs Summit Therapeutics Inc — how do they compare? CDW Corp. trades at $135.37 (market cap $16.92B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: CDW Corp. is the larger of the two by market cap, and CDW Corp. pays a 1.86% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CDW | SMMT | |
|---|---|---|
Market Cap | $16.92B | $12.06B |
Sector | Technology | Health |
52-Week High | $170.77 | $26.98 |
52-Week Low | $99.30 | $12.55 |
Enterprise Value | $22.52B | $11.39B |
Dividend Yield | 1.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CDW trades at $136.83, up 0.29% today, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $2.91, beating estimates, driven by 10% revenue growth from AI and infrastructure demand. However, margin compression and a CFO transition plan for 2027 present headwinds. The stock shows strong analyst support with a 70.59% buy rating and a $148.67 consensus price target.
Outlook remains positive due to solid fundamentals and AI-driven growth, but risks include margin pressure and leadership changes. The stock offers potential upside to the price target, though investors should monitor execution on profitability amid competitive and macroeconomic challenges.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
